Second dose of experimental drug may help heart amyloidosis patients
Disease control
Ongoing
This study tests whether a second round of treatment with ALXN2220 is safe and can improve heart function in people with transthyretin amyloid cardiomyopathy, a condition where abnormal proteins build up in the heart. About 35 adults who previously received the drug will get it a…
Phase: PHASE2 • Sponsor: Neurimmune AG • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC